Home/Arovella/Dr Nicole van der Weerden
DN

Dr Nicole van der Weerden

Chief Operating Officer

Arovella

Therapeutic Areas

Arovella Pipeline

DrugIndicationPhase
ALA-101CD19+ B‑cell lymphomas and leukaemiasPreclinical
ALA-105Claudin‑18.2+ gastric, gastro‑oesophageal junction, and pancreatic cancersPreclinical